Presenting at BIO-Europe Spring is the most direct way to get your innovative asset or idea directly in front of the right audience.
Biotech Company Presentations
In this track, biotech companies can partner their products, initiate strategic alliances and tap into the global financing network.
Midsize Pharma Presentations
This track reflects increased demand for midsize pharma presentations. Find your perfect fit partners.
Next Generation Presentations
This track is the most direct way for early stage projects and small entrepreneurial companies to get their innovative asset or idea directly in front of potential partners.
Academic Innovators Presentations
Academic researchers and technology transfer offices can apply to present their asset or idea to funding and development partners
We are happy to help. Please contact:
Matias Laquoi | EBD Group+49 89 2388 756 43 | email@example.com
The Selection Committee made up of industry experts:
Bayer – Mark Wolters, VP, Head of Early Licensing
Biotechnology Innovation Organization (BIO) – Bernard V. Fallon, Director, Industry Research
FHR Consult – Fritz Rudert, General Manager
Gemini Advisors – Wendy Johnson
Forbion – Sanders Slootweg, Managing Partner
Novo Nordisk – Florence Dal Degan, R&D Innovation Sourcing Director
Why present at BIO-Europe Spring?
Increase your company's visibility and generate interest among 2,600+ executives from over 50 countries
Pitch your company to top-tier VCs, pharma and private equity investors
Put your licensable asset on the opportunity map
Make sure that you open your talk/presentation with the most important thing you want your audience to know.
Donna L. LaVoie
President and CEO
Less is more: The more clear and concise the presentation, the more memorable it will be. Save the details for the Q&A session.
Start and end your presentation with why your audience should be interested by clearly and concisely describing the value and potential of the product/technology and why it is different from others out there. This will help to "hook" them in the beginning, and it will be the last thing they remember. Include supporting data in the middle, but don't overdo it.
Unless you are trying to sell your whole company, focus 90 percent of your presentation only on the asset(s) you are trying to partner and don't forget to include the clinical utility.
MacDougall Biomedical Communications, Inc.
Presenting companies must tell a compelling story to grab the interest of investors/partners. Much like a movie, if the plot (vision/objectives) has no action (milestones), and the characters (drug technology/pipeline) aren't brought to life (strong messages, visually appealing presentation), then those in the audience will not care.
Gregory Q. Tiberend
President and CEO
Tiberend Strategic Advisors, Inc.